<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title>Aegerion Pharmaceuticals, Inc. (AEGR): Aegerion: Addressable Market At Odds By 1,000% - Seeking Alpha</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8" />
<meta http-equiv="P3P" content='CP="IDC DSP COR ADM DEVi TAIi PSA PSD IVAi IVDi CONi HIS OUR IND CNT"' />

<script>
    (function(_,e,rr,s){_errs=[s];var c=_.onerror;_.onerror=function(){var a=arguments;_errs.push(a);
    c&&c.apply(this,a)};var b=function(){var c=e.createElement(rr),b=e.getElementsByTagName(rr)[0];
    c.src="//beacon.errorception.com/"+s+".js";c.async=!0;b.parentNode.insertBefore(c,b)};
    _.addEventListener?_.addEventListener("load",b,!1):_.attachEvent("onload",b)})
    (window,document,"script","4ffae9d6f05d1da630000008");
</script>

<script type='text/javascript'>
try {
  window.external.msSiteModeCreateJumplist('SeekingAlpha - Read, Decide, Invest.');
  window.external.msSiteModeAddJumpListItem('Portfolio' ,
  'http://seekingalpha.com/account/portfolio?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Market Currents - Real-time stock market news updates' ,
  'http://seekingalpha.com/currents/all?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Investment Ideas' ,
  'http://seekingalpha.com/dashboard/investing_ideas?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Income Investing, Retirement Investing and Dividend Stocks' ,
  'http://seekingalpha.com/dashboard/investing_income?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('ETFs & Portfolio Strategy' ,
  'http://seekingalpha.com/dashboard/etfs?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Macro View, Market Economy' ,
  'http://seekingalpha.com/dashboard/macro_view?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('My Email Alerts' ,
  'http://seekingalpha.com/account/email_preferences?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
} catch (ex) {
}
</script>
<meta name="application-name" content="Seeking Alpha - Read, Decide, Invest."/>
<meta name="msapplication-TileColor" content="#360000"/>
<meta name="msapplication-TileImage" content="http://static.cdn-seekingalpha.com/images/media_kit/71cdea92-2dc1-419d-8d62-f68b74c1eda8.png"/>
<meta name="msapplication-tooltip" content="Seeking Alpha - Read, Decide, Invest." />
<meta name="msapplication-starturl" content="http://seekingalpha.com?source=ie_task" />
<meta name="msapplication-task" content="name=Portfolio ;action-uri=http://seekingalpha.com/account/portfolio?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Market Currents - Real-time stock market news updates ;action-uri=http://seekingalpha.com/currents/all?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Investment Ideas ;action-uri=http://seekingalpha.com/dashboard/investing_ideas?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Income Investing, Retirement Investing and Dividend Stocks ;action-uri=http://seekingalpha.com/dashboard/investing_income?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=ETFs & Portfolio Strategy ;action-uri=http://seekingalpha.com/dashboard/etfs?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Macro View, Market Economy ;action-uri=http://seekingalpha.com/dashboard/macro_view?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=My Email Alerts ;action-uri=http://seekingalpha.com/account/email_preferences?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<!-- End IE9 Settings -->

<meta name="twitter:card" content="summary">
<meta name="twitter:site" content="@sa_popular">
<meta name="twitter:title" content="Aegerion: Addressable Market At Odds By 1,000%">
<meta name="twitter:description" content="RE: Aegerion Pharmaceuticals, Inc. (AEGR)
  Summary:
Aegerion is trying to convince investors that there can be a population of 3,000 HoFH patients in the US for its drug, "lomitapide"; Nobel Prize winners and scientists associated with Aegerion use numbers that are closer to 300.">
<meta name='twitter:image' content='http://static3.cdn-seekingalpha.com/images/users_profile/000/582/827/big_pic.png?1364139943'><link rel="search" type="application/opensearchdescription+xml" href="/javascripts/seeking.xml" title="SeekingAlpha Search" />
<meta name="description" content="Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR): Aegerion: Addressable Market At Odds By 1,000%" /><meta name="robots" content="noarchive" /><meta name="keywords" content="NASDAQ:AEGR" /><link rel="alternate" media="only screen and (max-width: 640px)" href="http://m.seekingalpha.com/article/1835142" /><meta property="og:image" content="http://static.cdn-seekingalpha.com/uploads/2013/8/19/social_sa_logo.png" />
<meta property="og:title" content="Aegerion: Addressable Market At Odds By 1,000%" />
<meta property="og:description" content="RE: Aegerion Pharmaceuticals, Inc. (AEGR)Summary:Aegerion is trying to convince investors that there can be a population of 3,000 HoFH patients in the US for its drug, &#34;lomitapide&#34;; Nobel Prize winners and scientists" />
<link rel="canonical" href="http://seekingalpha.com/article/1835142-aegerion-addressable-market-at-odds-by-1-000" />
<link href="http://static2.cdn-seekingalpha.com/stylesheets/performance_layout_packaged.css?1384857740" media="screen" rel="stylesheet" type="text/css" /><link href="http://static2.cdn-seekingalpha.com/stylesheets/performance_layout_b_packaged.css?1384857740" media="screen" rel="stylesheet" type="text/css" /><link href="http://static1.cdn-seekingalpha.com/stylesheets/article_packaged.css?1384857741" media="screen" rel="stylesheet" type="text/css" />
<script type="text/javascript">var block_script = true;var jhi = 0;</script>
<script type="text/javascript" src="/javascripts/getads.js"></script>


<script type="text/javascript">
  var users_on_site='2,663,957';
  var user_cookie={};

  function readCookie(name) {
    var cookie = document.cookie.match(new RegExp('(^|;)\\s*' + escape(name) + '=([^;\\s]*)'));
    return (cookie ? unescape(cookie[2]) : null);
  }

  function addToCookie(key,value) {
    var arr=user_cookie[key].split(',');
    arr.push(value);

    user_cookie[key]=arr.join(',');
  }
  if (document.location.protocol == "https:") {
    document.write('<scr'+'ipt src="/account/no_cookie_key"></scri'+'pt>');
  } else if (readCookie('user_cookie_key')) {
    document.write('<scr'+'ipt src="http://static.cdn-seekingalpha.com/account/cookie/'+readCookie('user_cookie_key')+'"></scri'+'pt>');
  } else if (readCookie('user_id')) {
    document.write('<scr'+'ipt src="http://seekingalpha.com/account/no_cookie_key"></scri'+'pt>');
  }
  
    (function(){
      var url='/article/1835142-aegerion-addressable-market-at-odds-by-1-000';
      if (location.pathname!=url){
        if (window.history && history.replaceState) history.replaceState("", "", url+location.search);
        else location.href=url+location.search;
      }
    })();

  var isThisMyFirstPV = false;
  var _comscore = _comscore || [];
  _comscore.push({ c1: "2", c2: "8500672" });
  (function() {
    var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true;
    s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js";
    el.parentNode.insertBefore(s, el);
  })();
  var _sf_startpt=(new Date()).getTime(); // chartbeat code
  var is_pro = false;
  if (document.location.protocol == "https:") {
    document.write('<link rel="shortcut icon" type="image/ico" href="https://seekingalpha-a.akamaihd.net/favicon.ico" />')
  } else {
    document.write('<link rel="shortcut icon" type="image/ico" href="http://static.cdn-seekingalpha.com/favicon.ico" />')
  }
  
    
  var ASSET_HOSTS = ["http://static.cdn-seekingalpha.com","http://static1.cdn-seekingalpha.com","http://static2.cdn-seekingalpha.com","http://static3.cdn-seekingalpha.com"];
</script>

<script type='text/javascript'>
  if (document.location.protocol !== "https:") {
    var crtg_nid="2227";
    var crtg_cookiename="cto_sa";
    var crtg_varname="crtg_content";
    function crtg_getCookie(c_name){ var i,x,y,ARRCookies=document.cookie.split(";");for(i=0;i<ARRCookies.length;i++){x=ARRCookies[i].substr(0,ARRCookies[i].indexOf("="));y=ARRCookies[i].substr(ARRCookies[i].indexOf("=")+1);x=x.replace(/^\s+|\s+$/g,"");if(x==c_name){return unescape(y);}}return'';}
    var crtg_content = crtg_getCookie(crtg_cookiename);var crtg_rnd=Math.floor(Math.random()*99999999999);
    var crtg_url=location.protocol+'//rtax.criteo.com/delivery/rta/rta.js?netId='+escape(crtg_nid);crtg_url+='&cookieName='+escape(crtg_cookiename);crtg_url+='&rnd='+crtg_rnd;crtg_url+='&varName=' + escape(crtg_varname);
    var crtg_script=document.createElement('script');crtg_script.type='text/javascript';crtg_script.src=crtg_url;crtg_script.async=true;
    if(document.getElementsByTagName("head").length>0)document.getElementsByTagName("head")[0].appendChild(crtg_script);else if(document.getElementsByTagName("body").length>0 && !SA.Utils.Env.isIE7)document.getElementsByTagName("body")[0].appendChild(crtg_script);
  }
</script>
<script src="http://static1.cdn-seekingalpha.com/javascripts/common_packaged.js?1384857701" type="text/javascript"></script>
<script src="http://static2.cdn-seekingalpha.com/javascripts/common2_packaged.js?1384857703" type="text/javascript"></script><script src="http://static2.cdn-seekingalpha.com/javascripts/common_article_packaged.js?1384857705" type="text/javascript"></script><script src="//partner.googleadservices.com/gampad/google_service.js" type="text/javascript"></script>
<script>
  if (SA.Data && SA.Data.Cache) {
    var adata = SA.Data.Cache.get('campaign_content');
  }
</script>

<script type="text/javascript">
  if ((user_email_cookie=readCookie('user_email')) && user_email_cookie.indexOf('@gmail.com')!=-1) {
    createCookie('user_email',(user_email_cookie.replace('@gmail.com','').replace(/\./gi,'').replace(/\+(.*?)$/,''))+'@gmail.com',365);
  }

  if (typeof(readCookie) == "function" && readCookie('user_vocation')) {
    createCookie('u_voc',readCookie('user_vocation'),3000);
  }
  if (readCookie('sapu') == "121") {eraseCookie('sapu');}
  var user_cookie = user_cookie || {};
  eraseCookie("__article_last_size");

if (top.location.pathname == "/" && readCookie('user_id')==957061) {
  var old_SADataCookies = SA.Data.Cookies.get;
  SA.Data.Cookies.get = function(x){if (x=="user_following_users" || x=="user_watchlist_authors") return ""; else return old_SADataCookies(x);}
}
  try{(function(){
    var uc=SA.Data.Cookies.get("user_cookie_key"), t=uc ? uc.match(/t=([0-9]+)/) : null;
    if (t && t[1] < 1367771521) SA.Data.Cookies.set("user_cookie_key","");
  })();} catch(e){}
</script>

<script type="text/javascript">var NREUMQ=NREUMQ||[];NREUMQ.push(["mark","firstbyte",new Date().getTime()]);</script>      <script type="text/javascript">
  var adblock = false;
  try{
    GS_googleAddAdSenseService("ca-pub-1420150919334552");
    GS_googleEnableAllServices();
  } catch(e) {
    adblock = true;
    Mone.event("Exception","adsense1","adsense down");
  }
</script>
<script type="text/javascript">
  try{
      GA_googleAddSlot_sa('Article_120x30');
    GA_googleFetchAds();
  } catch(e) {
    adblock = true;
    Mone.event("Exception","adsense2","adsense down");
  }
</script>  </head>
    <body class="stretch_bg">
    <script>
  var ms_slug = '';
  var article_dashboards = '@investing-ideas@';
  var article_sectors_themes = '@short-ideas@us@article@';
  var ratings_hash={};
  var ARTICLE_ID = 1835142;
  var ARTICLE_TYPE = "standard";
  var ARTICLE_LOCK = "";
  var author_slug = "matt-berry";
  var pticker_for_ads = "aegr";
  var time_left;
  var lock_comments = false;
  var machine_cookie = readCookie('machine_cookie');
  var middle_version = ABTest.identity%10;
  try {
    window.sessionStorage.setItem("/article/"+ARTICLE_ID, '1');
  } catch (error) {}

  
</script>
<script>var mone_article_tags = "{aegr};;;{};;;{short-ideas,us,investing-ideas};;;{matt-berry}"</script><script>var ord = Math.floor(Math.random()*1000000000);</script>
<span class="seeking_alpha_site_title">Seeking Alpha</span>
<script type="text/javascript">
  if (readCookie('sa_mobile') == '1') {
    var aHTML =[];
    aHTML.push('<div class="mobile_or_full_site">');
      aHTML.push('<span class="mobile_site" onclick="eraseCookie(\'sa_mobile\');top.location.reload()">Click here to view mobile site</span>');
      aHTML.push('<div class="cleaner"></div>');
    aHTML.push('</div>');
    document.write(aHTML.join(""));
  }
</script>
<div class="promotion_cnt finance stars ipad_top">
  <div close="close"></div>
    <a onclick='Mone.event("ipad_promotion_top","top_ipad_banner_large","ipad_promotion_top_click");' href="/download-ipad-app?source=top_ipad_banner_large" class="promotion_video">
    <div class="ptext">
      <div class="ptext_t">Seeking Alpha Portfolio App for iPad</div>
      <div class="ptext_h">Finance</div>
      <div id='ipad_stars' class="stars stars_5"></div>
      <div class="rate">(<span class="rate_num" id="rate_num">1</span>)</div>
    </div>

    <div class="free"></div>
    <div class="sep"></div>
    <div class="ipad_screenshots"></div>
  </a>
</div>
<script>
  var ipadData;
  SeekingAlpha.Initializer.AddAfterLoad(function(){
    if (SA.Utils.Env.isIPad && !/3/.test(SA.Data.Cookies.get("user_devices"))){
      Mone.event("ipad_promotion_top","top_ipad_banner_large","ipad_promotion_displayed");
      ipadData = new SA.Data.iPad();
      ipadData.instanceName = "ipadData";
      var responseHandler = new Object();
      responseHandler.handleResponse = function(data){
        if (!data.averageUserRating) return;
        var stars = data.averageUserRating < 4 ? "4" : (data.averageUserRating+"").replace(".","");
        $("ipad_stars").className = "stars stars_"+stars;
        $("rate_num").innerHTML = data.userRatingCount;
      }
      ipadData.responseDelegate = responseHandler;
      ipadData.getData();
    }
    if (SA.Utils.Env.isIPad && !/3/.test(SA.Data.Cookies.get("user_devices"))) {
      $$("body")[0].addClassName('ipad_promotion')
    }
  });
</script>
<div id="header" class="not_logged_in header_nav">
  <div id="logo_and_navigation" class="logo_and_primary_navigation">
    <div id="comment_popup" style="position:relative; left:0; display:none">
  <div id="popup_secondary">
    <div id="inner_popup"></div>
  </div>
</div>    <span class="logo_old_h1"><a href="http://seekingalpha.com/" title="Seeking Alpha - Home Page" sasource="salogo"></a></span>
    
      <div class="item banner728x90" id='top_banner_728x90'>
          <script type="text/javascript">
            iframeAd("728x90",'http://ad.doubleclick.net/adj/sek.investing-ideas/short-ideas;sz=728x90;x=x;tile=1;d=investing-ideas;t=short-ideas;aid=1835142;d=investing-ideas;t=short-ideas;t=us;t=article;z=1;a=matt-berry;cnt=7;cnt=23;cnt=24;pr=aegr;s=aegr;'+dart_my_vocation_and_profiles()+'ord='+ord+'?');
          </script>
      </div>
    
  </div>
  <div class='nav_container_wrap' id='nav_container_wrap'>
  <div id="nav_container" headtab="">
    <div id="navi_cont">
      <ul id="navi" class="navi">
        <li thistab='home' class="home">
          <a href="http://seekingalpha.com/" sasource="headtabs">Home</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='portfolio' class="portfolios">
          <a href="http://seekingalpha.com/account/portfolio" sasource="headtabs">Portfolio</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='market_news'>
          <a href="http://seekingalpha.com/currents/all" sasource="headtabs">Market Currents</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='investing_ideas'>
          <a href="http://seekingalpha.com/dashboard/investing_ideas" sasource="headtabs">Investing Ideas</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='investing_income'>
          <a href="http://seekingalpha.com/dashboard/investing_income" sasource="headtabs">Dividends &amp; Income</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='etfs'>
          <a href="http://seekingalpha.com/dashboard/etfs" sasource="headtabs">ETFs</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='macro_view'>
          <a href="http://seekingalpha.com/dashboard/macro_view" sasource="headtabs">Macro View</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='alerts'>
          <a href="http://seekingalpha.com/real-time-alerts" sasource="headtabs">ALERTS</a>
            <span class="navi_right_corner">|</span>
          </li>
          <li thistab='pro' class="pro_tab">
            <a href="http://seekingalpha.com/account/pro" sasource="headtabs">PRO</a>
          </li>
        <li class="right_section">
          <div id="user_settings_wrapper"></div>
        </li>
      </ul>
    </div>
  </div>
    <div class="rta_nav">
      <span class="rta_nav_wrap">
        <div id="rta_nav_close" onclick="SA.Promotion.Sticky.hide()" class="close_rta">&nbsp;</div>
        <div id="related_promo_container_rel_nav" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title_nav">This article was sent to <span id="promo_num_of_rta_rel_nav">1,041</span> people who get email alerts on <span class="replace_by_rel_slug">&nbsp;</span>.</div>
      <div class="title_sec">Which cover: new articles | breaking news | earnings results | dividend announcements</div>
  </span>
  <div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel_nav')">Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span></div>
  <div class="m_pop point_left" id="promotion_box_rel_nav" style="display:none;"></div>
</div>
<div id="related_promo_container_no_rel_nav" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to <span id="dash_newsl_subscr_count_ph_nav">371,146</span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel_nav', 10727)">Get the Investing Ideas newsletter &raquo;</span>
    <span id="promo_no_rel_loader_nav" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel_nav" style="display:none;"></div>
</div>
                              </span>
    </div>
</div>
  <script type="text/javascript">
    SeekingAlpha.Initializer.LogAndRun(SA.Navigation.Top.init);
  </script>
</div>
<div id="main_container" class="white_as_before ">
  <div id="content_wrapper" class="article_pages" itemscope itemtype="http://schema.org/Article">
    <img src="http://static.cdn-seekingalpha.com/images/universal/print_logo.png" width="48" height="20" id="print_seekingalpha_logo" />
    <div class="page_top">
      <div class="search_box_container_isolated">
  <div class="search_box">
    <form id="search_box_sa_search" method="get" class="linktosym comp search" action="/search/" onsubmit="return false;">
      <fieldset>
        <input id="autocomplete_sa_search" class="input_text text" type="text" value="search by symbol, author, keyword..." size="25" autocomplete="off" onblur="if($$('.search_box'))$$('.search_box')[0].style.background='';this.style.color=this.value=='' ? '#8D8D8D' : '#000000';handleInput(this,'blur')" onfocus="if($$('.search_box'))$$('.search_box')[0].style.background='#fff';this.style.color='#000000';handleInput(this,'focus')" afteruploadvalue='eFind quotes, people, expressions, transcripts' title='search by symbol, author, keyword...' class="find_transcripts" />
        <input type="button" class="search_button" value="" onclick="if ($('autocomplete_sa_search').value!=$('autocomplete_sa_search').title) AutoCompleteSAConfig.Packages.search.Find()" />
      </fieldset>
      <input type="hidden" name="source" value="search_general" />
      <input type="hidden" id="autocomplete_sa_hidden_search" name="q" value="" />
      <input type="hidden" name="cx" value="018269914407235029540:cdhc2yeo2ko" />
      <input type="hidden" name="cof" value="FORID:11;NB:1" />
      <input type="hidden" name="goto_search_tab" value="" />
    </form>
    <script type="text/javascript">SeekingAlpha.Initializer.LogAndRun(function () { AutoCompleteSAConfig.Load('search', { Symbols:true, IframeCover:true, AfterInsert:function () { this.Find(); }, AfterSubmit:function () { this.Find(); }}) });</script>
    <script type="text/javascript" src="http://www.google.com/coop/cse/brand?form=searchbox_018269914407235029540%3Acdhc2yeo2ko&lang=en"></script>
  </div>
</div>
      <div id="article_header" class="article_content">
  <div class="top_content">
    <div id="page_header" class="page_header_email_alerts">
      <h1>
        <span itemprop="name">Aegerion: Addressable Market At Odds By 1,000%</span>
              </h1>
      <div id="article_info">
        
        <div class="article_info_pos">
          <span>Nov 13 2013, 03:51</span>
          <span id='title_article_comments'></span>
          <span id="page_position"></span>
          <span class="author_name_for_print">by: Matt Berry</span>
<span  class='print_hide'>&nbsp;|&nbsp;</span>
            <span class='print_hide'>about:</span> <span  class='print_hide' id='about_primary_stocks'><a href="/symbol/aegr" title='Aegerion Pharmaceuticals' sasource='article_primary_about'>AEGR</a></span>                   	</div>
        <div id="bookmark_top" class="bookmark_container">
  <div id="bookmark_title_top" class="bookmark_title">BOOKMARK<span class="added">ED</span><span class="add"> / READ LATER</span></div></span>
  <div class="bookmark_popup" id="bookmark_popup_top">
    <h2>Bookmarked</h2>
    <p>Added to your bookmarks on the Seeking Alpha homepage</p>
    <div id="btn_top" class="btn">Remove Bookmark</div>
    <div class="arr"></div>
    <div class="right_cor"></div>
  </div>
</div>
<script>
 new SA.Pages.Article.bookmark("_top");
</script>
      </div>
    </div>
  </div>
</div>
<div class="cleaner"></div>
    </div>
    <div class="cleaner"></div>
    <div id="main_content" class="no_big_gaps_main_content">
      
      <div id="article_body_container" class="no_big_gaps_article_body_container" style="float:right;">
        <div id="article_body" itemprop="articleBody">
          <div id="article_body_top2" class="disclosure_top" style="display:none;"></div>
          <p>RE: Aegerion Pharmaceuticals, Inc. (<a href='http://seekingalpha.com/symbol/aegr' title='Aegerion Pharmaceuticals'>AEGR</a>)</p><p><strong>Summary:</strong></p><p>Aegerion is trying to convince investors that there can be a population of 3,000 HoFH patients in the US for its drug, "lomitapide"; Nobel Prize winners and scientists associated with Aegerion use numbers that are closer to 300.</p><p><strong>Background:</strong></p><p>Aegerion is in a race against Isis, Amgen, Sanofi and others to provide another treatment for those afflicted with <a href="http://en.wikipedia.org/wiki/Familial_hypercholesterolemia#Homozygous_FH.org/" target="_blank" rel="nofollow">Homozygous Familial Hypercholesterolemia</a> (HoFH), an extremely rare, yet very serious disease leading to excessive levels of cholesterol. Before modern treatments, such as apheresis and statins, most patients did not live beyond 30 years of age. Isis' new drug, called "Mipomersen," has just been approved this year by the FDA. Competing with this new drug is Aegerion's drug, "Lomitapide."</p><p><img src="http://static.cdn-seekingalpha.com/uploads/2013/11/11/582827-13842224311348999-Matt-Berry.jpg" align="left" alt="AEGR Market Cap versus 2013 Revenue" hspace="6" vspace="6" />Aegerion has only one drug on the market. As the SEC filings put it, "Our business currently depends entirely on the success of JUXTAPID." (AKA, "lomitapide.") ~ (<a href="http://www.sec.gov/Archives/edgar/data/1338042/000119312513112185/d447885d10k.htm" target="_blank" rel="nofollow">AEGR 2012 10-K</a>)</p><p>Aegerion currently has a <a href="http://finance.yahoo.com/q/ks?s=AEGR+Key+Statistics" target="_blank" rel="nofollow">market cap of about $2 billion</a>, with "full year 2013 revenue guidance for net product sales to $45 to $50 million …" ("<a href="http://finance.yahoo.com/news/aegerion-pharmaceuticals-announces-third-quarter-110000457.html" target="_blank" rel="nofollow">Aegerion Pharmaceuticals Announces Third-Quarter 2013 Financial Results</a>")</p><p>A controversy surrounds Aegerion's claimed patient population: management has been promoting the idea that there are 3,000 HoFH cases in the USA; scientists associated with Aegerion put the number closer to 300. That is a 1,000% difference.</p><p><strong>The Patient Count Controversy:</strong></p><blockquote class='quote'>"… consistent with our plan to discontinue offering specific launch metrics other than sales, we no longer plan to provide guidance for the number of patients on therapy at year end." (<a href="http://seekingalpha.com/article/1586952-aegerion-pharmaceuticals-management-discusses-q2-2013-results-earnings-call-transcript" target="_blank">Q2 2013 Conference Call</a>)</blockquote><p>Why not?</p><p>With Aegerion's decision to stop revealing patient counts, we have only underlined an older suspicion: the estimate of HoFH patients in the USA as used by the very scientists associated with Aegerion may be correct and consequently, the actual U.S. HoFH patient count promoted by the CEO would be a 1,000% exaggeration … 90% lower than Aegerion's promotional material suggests.</p><table border="1" cellpadding="1" cellspacing="1" class="designed_table"><tr><td>Aegerion relationship</td><td><strong>Estimation of USA HoFH population</strong></td></tr><tr><td>Marc Beer, CEO of Aegerion</td><td>3,000</td></tr><tr><td>Dr. Marina Cuchel, top listed scientist on Aegerion's phase 3 study for Lomitapide.</td><td>300</td></tr><tr><td>DR. Daniel J. Rader, "the inventor of the patent."</td><td>300</td></tr></tbody></table><p><strong>More detail:</strong></p><p>Marc Beer, CEO of Aegerion uses "3,000" which would be a prevalence of 1:100,000.</p><blockquote class='quote'><p>"... there may be as many as 15,000 potential patients appropriate for lomitapide therapy in total on a global basis, with at least 3,000 of them being in the U.S." (<a href="http://seekingalpha.com/article/1586952-aegerion-pharmaceuticals-management-discusses-q2-2013-results-earnings-call-transcript" target="_blank">Q2 2013 Conference Call</a>)</p><p>"… I would emphasize that what we're seeing in the marketplace is just reconfirming that 3,000-plus U.S. number, that 15,000 -- approximately 15,000 patients globally, and we feel comfortable committing that we can get 4,000 to 5,000 patients on therapy globally and have this exceed $1 billion of revenue per year." (<a href="http://seekingalpha.com/article/1790502-aegerion-pharmaceuticals-management-discusses-q3-2013-results-earnings-call-transcript" target="_blank">Q3 2013 Conference Call</a>)</p></blockquote><p>Dr. Marina Cuchel, top listed scientist on Aegerion's lomitapide phase 3 study uses a prevalence of "1:1,000,000," which comes out to about 300 patients in the USA. (To see her relationship to Aegerion, follow the links to <a href="http://www.aegerion.com/Collateral/Documents/English-US/AHA_2009_-_Lomitipide_treated_HoFH_patients_-_6_month_results.pdf" target="_blank" rel="nofollow">Dr. Cuchel's presentation poster</a> | <a href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2961731-0/fulltext" target="_blank" rel="nofollow">Lancet</a>)</p><ul><li>See her <a href="http://www.youtube.com/watch?v=_qMnZxvFFvU" target="_blank" rel="nofollow">YouTube presentation</a> of Aegerion's Lomitapide, in which she also mentions HoFH prevalence in the first minute. Quote from 0:30 into the video:</li></ul><blockquote class='quote'><p>"... for a very rare disease: that is Homozygous Familial Hypercholesterolemia. The incidence is calculated to be one in a million, so about 300 patients in the United States."</p></blockquote><p>Dr. Daniel J. Rader, introduced by Aegerion as "the inventor of the patent," uses a prevalence of "1:1,000,000," which comes out to about 300 patients in the USA.</p><blockquote class='quote'>"The estimated prevalence of homozygous FH is approximately 1 in a million people." (<a href="http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM340371.pdf" target="_blank" rel="nofollow">Presentation before the FDA committee</a>)</blockquote><p>To see the relationship between AEGR and Dr. Rader, follow this link: <a href="http://ir.aegerion.com/releasedetail.cfm?ReleaseID=572091" target="_blank" rel="nofollow">Aegerion's press release</a>.</p><p><em>(click to enlarge)</em><a href="http://static.cdn-seekingalpha.com/uploads/2013/11/11/582827-13842153768802238-Matt-Berry_origin.jpg" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/11/11/582827-13842153768802238-Matt-Berry.jpg" align="middle" alt="AEGR Dr Rader citing prevalence of 1 in a million in FDA meeting" hspace="6" vspace="6" /></a></p><p>Aegerion financially supported a study on the prevalence of HoFH in Germany and that study estimated a prevalence of 1:860,000.(<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647446/" target="_blank" rel="nofollow">Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey</a>) As of this writing, the U.S. population is about 317 million. (<a href="http://www.census.gov/popclock/" target="_blank" rel="nofollow">US Census Population Clock</a>) Even if this <br>German study and its higher prevalence rate were representative of U.S. rates, these numbers would still estimate the U.S. population of HoFH patients to be somewhere between 300 and 400. That's a serious drop from Aegerion's promotion of 3,000.</p><p>The scientific community generally uses the number 300 for the U.S. -- that is, a prevalence rate of 1:1,000,000. This prevalence rate has been widely accepted and published. It is even used by Nobel Prize winners, Michael S. Brown and Joseph L. Goldstein. Their research, as described on the official website for the Nobel Prize, mentions the prevalence rate: "The severe form of FH (homozygous) is rare, about one in a million people."(<a href="http://www.nobelprize.org/nobel_prizes/medicine/laureates/1985/press.html" target="_blank" rel="nofollow">The Official Web Site of the Nobel Prize</a>)</p><p>This latter number is even used in Michael Brown's Nobel Prize acceptance speech:</p><p><em>(click to enlarge)</em><a href="http://static.cdn-seekingalpha.com/uploads/2013/11/11/582827-13842155034595106-Matt-Berry_origin.jpg" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/11/11/582827-13842155034595106-Matt-Berry.jpg" align="middle" alt="Nobel Prize winner Michael Brown citing HoFH prevalence rate in acceptance speech" hspace="6" vspace="6" /></a></p><p>Follow the link to the official website of the Nobel Prize organization: <a href="http://www.nobelprize.org/mediaplayer/index.php?id=1676" target="_blank" rel="nofollow">Video of Nobel Prize winner</a>, Michael Brown, using prevalence rate of 1:1,000,000 for HoFH. The prevalence rate is mentioned and illustrated 11:47 minutes into the video.)</p><p>Perhaps it's possible that those with a Wall Street interest in prevalence rates know more than the scientific community, or perhaps some people just get high by smoking their own math. Me, I think I'll bet on what the scientists are saying.</p><p>What is AEGR worth with 3,000 U.S. and 15,000 global patients? … but if investors have been misled and the number is actually 90% less, what will we value AEGR's stock price with a U.S. patient population of only 300? Here is a claim made in the third quarter conference call:</p><blockquote class='quote'>"… I would emphasize that what we're seeing in the marketplace is just reconfirming that 3,000-plus U.S. number, that 15,000 -- approximately 15,000 patients globally, and we feel comfortable committing that we can get 4,000 to 5,000 patients on therapy globally and have this exceed $1 billion of revenue per year." (<a href="http://seekingalpha.com/article/1790502-aegerion-pharmaceuticals-management-discusses-q3-2013-results-earnings-call-transcript" target="_blank">Conference Call Q3 2013</a>)</blockquote><p>But investors currently value Aegerion at a 2 billion dollar market cap, about $70 ~ $80 per share -- as if all of these sales have already taken place and as if there were no issue of an exaggerated patient population. If the generally accepted prevalence rate ends up being correct and if the market adjusts revenue estimates down 90%, what stock price will we adjust to? 90% down from here would be about $7 or $8 per share. That'd be a serious drop.</p><p><a href="http://ycharts.com/companies/AEGR/chart/#/?series=mut:,agg:last,freq:,calc:market_cap,type:company,id:AEGR,,&amp;maxPoints=480&amp;zoom=5&amp;format=real" target="_blank" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/11/11/saupload_aab8e5a068d4ce94c60121f1edb7f972.png" alt="AEGR Market Cap Chart" /></a></p><p>I called Investor Relations at Aegerion and did not receive any information that was not already made available through filings, conference calls, and the Investor Day presentation. To sum up the conversation, Aegerion held to the 3,000 patient count. Their data is "proprietary," and there is no "third party peer reviewed" information that I could receive. A patient tracker was said to list 1,500 patients, with the "vast majority" being from the United States. Based on this tracker, contact with doctors, and other data, they are deriving their 3,000 patient count for the US. This data is not publicly available, so we are left with trusting management for both the data and the method of calculation. When I asked for publicly available sources, they pointed out the European Heart Journal article featured on Investor Day. Let's take a look at that article.</p><p>Aegerion held its "<a href="http://wsw.com/webcast/cc/aegr/" target="_blank" rel="nofollow">Investor Day</a>" on November 7, 2013. In it CEO Mark Beer refers to a <a href="http://eurheartj.oxfordjournals.org/content/early/2013/08/15/eurheartj.eht273.full" target="_blank" rel="nofollow">paper in the European Heart Journal</a>, which supports, by "extrapolation," what Aegerion has been trying to tell investors: there might be more HoFH patients than generally accepted by the scientific community. (<a href="http://wsw.com/webcast/cc/aegr/" target="_blank" rel="nofollow">CEO Beer Investor day</a>. Time: 9:10 minutes into presentation)</p><p>9:10 minutes into the <a href="http://wsw.com/webcast/cc/aegr/" target="_blank" rel="nofollow">presentation</a>, CEO Beer. said,</p><blockquote class='quote'>"We had nothing to do actually with this publication."</blockquote><p>This is clearly not the case. One only needs to scroll down to page 12 to see that Aegerion put up some money here.</p><p><em>(click to enlarge)</em><a href="http://static.cdn-seekingalpha.com/uploads/2013/11/11/582827-13842156369691133-Matt-Berry_origin.png" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/11/11/582827-13842156369691133-Matt-Berry.png" align="middle" alt="CEO Beer claims Aegerion had nothing to do with the paper cited on Investor day" hspace="6" vspace="6" /></a></p><blockquote class='quote'>"Conflict of interest: Consensus Panel members have received lecture honoraria, consultancy fees and/or research funding from Aegerion (M.J.C., R.D.S., M.A., A.L.C., K.G.P., E.B.) ~ , …." (<u>European Heart Journal paper cited on Investor Day)</u></blockquote><p><strong>What about the <em>original</em> paper?</strong></p><p>Familiar Hypercholesterolemia (FH) has a severe form, H<strong><u><em>e</em></u></strong>FH, and an extremely severe and extremely rare form, H<u><em><strong>o</strong></em></u>FH. The fact that the study focused on HeFH and not HoFH is not a concern, since HoFH is related to HeFH. "HeFH" refers to Heterozygous FH (inherited from only one parent) and HoFH, to Homozygous FH (inherited from both parents). So when the study challenges the widely accepted HeFH prevalence of 1:500 with the new number 1:200, we should accept that, if true and representative of the general population, this would have a bearing on HoFH prevalence rates. So far, so good.</p><p>On Investor Day, this new prevalence rate of 1:200 for HeFH is extrapolated into a prevalence rate for HoFH of 1:160,000, ending with an patient population of 2,000 in the U.S. But how did we get this rate 1 in 200?</p><p>Why would Aegerion use the paper from the European Heart Journal and not use the original paper from which the European Heart Journal derived the information, lumping "Definite" FH patients together with "Probable" FH patients. When we read the text we learn that the paper is <em>recommending a scoring system</em> which will categorize candidates for FH into degrees of probability. Now we can lump "probable patients" with "definite patients" and show everyone a higher prevalence rate. In the original paper, however, you can see these scores separately, and, surprise, surprise, the prevalence for Definite FH is the same old 1:500. Lumped together in the European Heart Journal we naturally come up with a higher prevalence rate.</p><p><em>(click to enlarge)</em><a href="http://static.cdn-seekingalpha.com/uploads/2013/11/11/582827-13842157590706024-Matt-Berry_origin.png" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/11/11/582827-13842157590706024-Matt-Berry.png" align="middle" alt="Prevalence rate for the Danish study was actually the traditional 1 in 500 for Definite FH" hspace="6" vspace="6" /></a></p><ul><li>Cited by Aegerion on Investor day: <a href="http://eurheartj.oxfordjournals.org/content/early/2013/08/15/eurheartj.eht273.full" target="_blank" rel="nofollow">Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease</a>. (cited by Aegerion on Investor Day)</li><li>Source for paper cited by Aegerion on Investor Day: <a href="http://jcem.endojournals.org/content/early/2012/08/13/jc.2012-1563.abstract" target="_blank" rel="nofollow">Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication</a></li></ul><p><img src="http://static.cdn-seekingalpha.com/uploads/2013/11/11/582827-13842159437071621-Matt-Berry.png" align="right" alt="Original paper was also funded by pharmaceutical players in this market" hspace="6" vspace="6" />Do we even need to mention that two of the authors on the <a href="http://jcem.endojournals.org/content/early/2012/08/13/jc.2012-1563.abstract" target="_blank" rel="nofollow">original paper</a> also received funds from pharmaceutical players? Do we need to mention that there are players here who have a financial interest in finding a larger pool of patients rather than a smaller one?</p><p>And do we really have a right to make assumptions on the U.S. population of HoFH patients from this particular study?</p><p>What is not immediately apparent is that this was a very specific study of "whites of Danish descent." How representative would that be of a melting pot such as the U.S. population? Additionally, the findings are contradicted by a previous study of 10,000 Danish infants which estimated an HeFH prevalence of 1:995. There is a serious gap of several hundred percent between two different studies, both estimating Danish prevalence rates for HeFH.</p><blockquote class='quote'>"11 infants were diagnosed with FH in a screening of 10,440 Danish newborns" (<a href="http://aje.oxfordjournals.org/content/160/5/407" target="_blank" rel="nofollow">Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review, Melissa A. Austin, et al.</a>)</blockquote><p>(10,440 / 11 = 1 in 949)</p><p>From the same source, Table 4, page 413:</p><table border="1" cellpadding="1" cellspacing="1" class="designed_table"><tr><td>Country/ethnicity</td><td>Estimated frequency of FH heterozygotes</td><td>Reference</td></tr><tr><td>Denmark/Danish</td><td>1/950 Individuals</td><td>Anderson,k et al., 1979</td></tr></tbody></table><br>(Ibid.)<p>Another study which Aegerion did not mention is one which it also funded and which determined an HoFH prevalence rate in neighboring Germany of 1:860,000. (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647446/" target="_blank" rel="nofollow">Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey</a>)</p><p>In fact, many studies have been done by others regarding the prevalence rates for HeFH and HoFH.</p><blockquote class='quote'>"The prevalence of FH is well-defined: it is one of the most common genetic disorders. Heterozygotes number about 1:500 persons in the general population, increasing to 1:50 when a founder effect is present, such as in French Canadian, Finnish, Christian Lebanese and South African populations." (<a href="https://www.lipid.org/communications/lipid_spin/2013W01" target="_blank" rel="nofollow">Kaye-Eileen Willard, MD, ABIM Medical Director for Chronic Disease Management Wheaton Franciscan Healthcare All Saints Cardiovascular Institute</a>)</blockquote><p>So we're not without a sample of prevalence counts, none of which should be taken off the table. A study in the UK put the prevalence of HeFH at 1:623; in Japan, at 1:900. In the illustration below, note that the numbers for the USA were derived from a Nobel Prize winner's research, <a href="http://www.nobelprize.org/nobel_prizes/medicine/laureates/1985/goldstein-lecture.html" target="_blank" rel="nofollow">Joseph L. Goldstein</a>, and were estimated to be in a range of 1:500 and 1:1000. (<a href="http://aje.oxfordjournals.org/content/160/5/407" target="_blank" rel="nofollow">Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review</a>)</p><p><em>(click to enlarge)</em><a href="http://static.cdn-seekingalpha.com/uploads/2013/11/11/582827-13842160725074406-Matt-Berry_origin.png" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/11/11/582827-13842160725074406-Matt-Berry.png" align="middle" alt="There have many studies on HeFH prevalence" hspace="6" vspace="6" /></a></p><p class='yc_font'><a href="http://ycharts.com/companies/AEGR/market_cap" dofollow="true" target="_blank">AEGR Market Cap</a> data by <a href="http://ycharts.com" dofollow="true" target="_blank">YCharts</a></p><p><strong>The Danish studies cited by Aegerion on Investor Day:</strong></p>
            <div id="article_source">Source: <a href="/article/1835142-aegerion-addressable-market-at-odds-by-1-000?source=cc">Aegerion: Addressable Market At Odds By 1,000%</a></div>
            <!--googleoff: index-->
            <div id="article_body_top" class="disclosure_top" style="display:none;">
              <p><strong>Disclosure: </strong>I am short <a href='http://seekingalpha.com/symbol/aegr' title='Aegerion Pharmaceuticals'>AEGR</a>. <span id="additional_business_disclosure" style="display:none">I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.</span> <span onclick='uncollapse()' id='more_button' style='cursor:pointer'><strong>(More...)</strong></span></p>
              <span id="business_disclosure" style="display:none"></span>
            </div>
            <div style="clear:both"></div>
            <!--googleon: index-->
          
        </div>
        <script>SA.Pages.Article.handleDisclosures();</script>
        <div id="content_follow_up" class="underbar">
          <div id="follow_wrap">
              <div id="article_rta_bottom_container">
                <div id="related_promo_container_rel" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title">
      This article was sent to 
      <span id="promo_num_of_rta_rel">1,041</span>
      people who get email alerts on 
      <span class="replace_by_rel_slug">&nbsp;</span>.
    </div>
  </span>
  <div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel');">
    Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span>
  </div>
  <div class="m_pop point_left" id="promotion_box_rel" style="display:none;"></div>
</div>

<div id="related_promo_container_no_rel" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to
    <span id="dash_newsl_subscr_count_ph">
      371,146
    </span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel', 10727)">
      Get the Investing Ideas newsletter &raquo;
    </span>
    <span id="promo_no_rel_loader" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel" style="display:none;"></div>
</div>
<div class="fl mb10" id="roadblock_comment_unit" style="display:none">
  <div class="comments_top_area">
    <div class="comments_top_area_half">
      <div class="comments_top_area_add"><strong>Comments</strong>
      	<span id="general_comment_counter">(<span id="comments_block"></span>)</span>
      </div>
    </div>
    <div style="color:#FF6F00">
      This article has&nbsp;
      <span id="comments_block2"></span>
      &nbsp;comments. To read them or add your own, <a href="javascript:void(0)" onclick="rb=new roadblock('article crb');rb.register_show=comments_reg_show;comments_reg_show()">click here</a>.
    </div>
  </div>
</div>

<div id="techpromo_container" style="display:none" class="fl mt30 mb30 w100">
  <div id="techpromo_button" onclick="SA.Pages.Article.sendTechPromoMail()"></div>
</div>

<div id="ipadpromo_container" style="display:none" class="fl mt30 mb30 w100">
  <div id='sms_promo_line1' class='sms_line1 ml90'>The #1 Portfolio App is Now on iPad!</div>
  <div id='sms_promo_line2' class='sms_line2 ml5 fwb mt10'>Get instant notifications & never miss a critical update on your stocks!</div>
  <a href="http://seekingalpha.com/download-ipad-app?source=article_ipad_app&kind=ipad" class="fl mt30"><div id="ipadpromo_button"></div></a>
  <a href="http://seekingalpha.com/download-ipad-app?source=article_ipad_app&kind=ipad" class="fl mt20"><div id="get_the_app"></div></a>
  <div id="ipadpromo_stars" class="fl mt15"></div>
</div>

<div id="store_container" style="display:none" class="fl mt30 mb30 w100">
  <div id='sms_promo_line1' class='sms_line1 ml25'>Which Seeking Alpha App is best for you?</div>
  <div class="mt15">
    <div class="ml25">
      <div class="fl"><input id="app_portfolio" type="checkbox"/></div>
      <div class="fl fwb ml10">Seeking Alpha Portfolio</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="ml25 mt15">
      <div class="fl"><input id="app_tech" type="checkbox"/></div>
      <div class="fl fwb ml10">Tech Investor</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="ml25 mt15">
      <div class="fl"><input id="app_etf" type="checkbox"/></div>
      <div class="fl fwb ml10">ETF investor</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="ml25 mt15">
      <div class="fl"><input id="app_energy" type="checkbox"/></div>
      <div class="fl fwb ml10">Energy Investor</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="light-gray mt20 ml25">Email me a link to open from my phone:</div>
    <div class="ml25 mt5">
      <input id="email_to_download" type="text" style="width: 300px" class="fl" emailautofill="on" title="Email address" empty="Email address"/>
      <div class="bs-btn fl btn-primary ml10 btn-mini fwb" style="width: 70px;" onclick="SA.Pages.Article.sendLinkDownload()">Continue</div>
      <div class="cb"></div>
      <div class="red fs11" id="email_td_error"></div>
    </div>
  </div>
</div>

<div id="web_video_container" style="display:none" class="fl mt30 mb30">
  <iframe width="480" height="315" src="//www.youtube.com/embed/LFNN6lhLtkk" frameborder="0" allowfullscreen></iframe>
  <div class="fl mt20" style="margin-left: 194px;"><a href="http://seekingalpha.com/download-app?source=vid_bottom_article">Get the app &raquo;</a></div>
</div>

<div id="ipad_video_container" style="display:none"  class="fl mt30 mb30">
  <iframe width="480" height="315" src="//www.youtube.com/embed/zEnMPGkjOnI" frameborder="0" allowfullscreen></iframe>
  <div class="fl mt20"  style="margin-left: 194px;"><a href="http://seekingalpha.com/download-app?source=vid_bottom_article">Get the app &raquo;</a></div>
</div>


              </div>
              <div id="article_rta_middle_container" style="display:none">
                <div id="related_promo_container_rel2" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title2">
      <span id="promo_num_of_rta_rel2">
         1,041
      </span>
         &nbsp;people received this article by email alert
         <span id="second_line_midelena"><br />Add your email to get alerts on <span class="replace_by_rel_slug">&nbsp;</span> too:</span>
    </div>
  </span>
  <div id="no_checkbox_midelena"><div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel2')">Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span></div></div>
  <div class="m_pop point_left" id="promotion_box_rel2" style="display:none;"></div>
</div>
<div id="related_promo_container_no_rel2" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to <span id="dash_newsl_subscr_count_ph2">371,146</span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel2', 10727)">Get the Investing Ideas newsletter &raquo;</span>
    <span id="promo_no_rel_loader2" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel2" style="display:none;"></div>
</div>

              </div>
     		    <div id="article_tags" style="display:none">
              <div itemprop="articleSection" class="tagged_with">
                <span class="tagged_with_label">Tagged: </span><a href='/dashboard/investing_ideas' sasource='article_navigation'>Investing Ideas</a>, <a href='/analysis/investing-ideas/short-ideas' sasource='article_navigation'>Short Ideas</a>
              </div>
	          </div>
            <div class="share_this_page_article_bottom">
              <ul id="page_toolbar" class="page_toolbar">
  <li class="share_this_page_article_toolbar">
    <div class="share_this_page_snippet">
  <div id="first_line_info" style="width:490px">
    <div class="left"><h6><span id="share_slogan" class="fs16">Share this article with a colleague</span></h6></div>
  </div>
  <div class="widgets">
    <!-- Email -->

      <span class="email_this" onclick="email_story_to_friends('Article',1835142,'http://seekingalpha.com/article/1835142-aegerion-addressable-market-at-odds-by-1-000')">
        <div class="email_button"></div>
        <div class="email_bubble">
          <span id="widget_email_count"></span>
          <span class="cor_right"></span>
        </div>
      </span>
    <!-- twitter -->
    <span class="twitter_small">
        <a href="https://twitter.com/share" class="twitter-share-button twitter_share" data-text="Aegerion: Addressable Market At Odds By 1,000% http://seekingalpha.com/article/1835142-aegerion-addressable-market-at-odds-by-1-000?source=tweet $AEGR" data-related="salphatrending" data-url=" " data-counturl="http://seekingalpha.com/article/1835142-aegerion-addressable-market-at-odds-by-1-000?source=share" data-count="horizontal">Tweet</a>
    </span>
    <!-- Linked In -->
      <span id="linkedin_1" class="linkedin_small linkedin_share"><script type="IN/Share" data-counter="right" data-onsuccess="linkedin_callback"></script></span>
    <!-- facebook -->
    <span class="facebook_small facebook_share"><div class="fb-like" data-href="http://seekingalpha.com/article/1835142-aegerion-addressable-market-at-odds-by-1-000?source=facebook" data-send="false" data-layout="button_count" data-show-faces="false" data-font="tahoma"></div></span>
    <!-- Plusone  -->
      <span class="plusone_wrap"><span class="plusone plusone_share"><div class="g-plusone" data-size="medium" annotation="bubble" data-width="65" data-callback="plusone_callback"></div></span></span>
    <!-- print -->
      <span class="print_this" onclick="print_article('with_comments')"><Print><div class="print_button"></div></span>
  </div>
</div>

  <script>
    SeekingAlpha.Initializer.AddAfterLoad(function(){
      new Ajax.Updater({success: 'widget_email_count'}, '/form/ajax_get_email_count', {
        method: 'get',
        parameters: {
          item_name: 'Article',
          article_id: '1835142'
        }
      });
    });
  </script>
  </li>
</ul>            </div>
            <div class="bookmark_bottom_wrapper"><div id="bookmark_bottom" class="bookmark_container">
  <div id="bookmark_title_bottom" class="bookmark_title">BOOKMARK<span class="added">ED</span><span class="add"> / READ LATER</span></div></span>
  <div class="bookmark_popup" id="bookmark_popup_bottom">
    <h2>Bookmarked</h2>
    <p>Added to your bookmarks on the Seeking Alpha homepage</p>
    <div id="btn_bottom" class="btn">Remove Bookmark</div>
    <div class="arr"></div>
    <div class="right_cor"></div>
  </div>
</div>
<script>
 new SA.Pages.Article.bookmark("_bottom");
</script></div>
	          <div id="article_bottom_about" class="article_bottom_units"></div>
            <div id="more_by_auth" class="more_by_auth"></div>
            <div id="more_by_ticker" class="article_bottom_units"></div>
            <div id="temporary_place_holder" class="mt10"></div>
            <div class="cleaner"></div>
          </div>
            <div class="comments_with_more">
              <div id="comments_section">
              </div>
            </div>
          <div class="cleaner"></div>
          <span class="article_submit_an_article_big" onclick="submit_your_article();"></span>
        </div>
      </div>
      <div id="secondary_ads" class="no_big_gaps_secondary_ads" style="float:right;">
        <div id="author_avatar">
    <div class="follow_sidebar">
      <script>var author_info_popup_timeout;</script>
<div id="author_info"> 
  <div class="author_page_tools" id="author_image_header">
    <div class="author_info_wrap">
      <a href="/author/matt-berry" class='this_is_a_author_pic' sasource="about_lpic"><img class="this_is_a_author_pic_img" align="center" src="http://static3.cdn-seekingalpha.com/images/users_profile/000/582/827/big_pic.png?1364139943" width="115" height="115" alt="Matt Berry picture" onmouseover="ShowAuthorInfo();" onmouseout="HideAuthorInfo();" /></a>
 <div id="goto_edit_picture" class="goto_edit_picture" style='display:none'><span onclick="return goto_update_picture();" onmouseover="ShowAuthorInfo();" onmouseout="HideAuthorInfo();"></span></div>
        <div id="article_author_info" style="display:none;" onmouseover="clearAuthorInfoPopupTimeout();" onmouseout="HideAuthorInfo();">
          <div>
            <div class="followup_contributor_info">
  <div class="followup_contributor_info_title">
    <span>About the author: </span>
    <a href="/author/matt-berry" sasource="about_name">Matt Berry</a>
  </div>

  <div class="followup_contributor_info_on_author">
    <div class="followup_contributor_info_pic_cont">
      <div class="pic_cont">
        <div class="pic_contributor">
          <div class="the_pic">
              <a href="/author/matt-berry" sasource="about_pic"><img align="center" width="54" height="54" src="http://static3.cdn-seekingalpha.com/images/users_profile/000/582/827/big_pic.png?1364139943" alt="Matt Berry picture"/></a>
          </div>
        </div>
      </div>
    </div>
    <div class="followup_contributor_info_text">
      Blog with (mostly) shorts. I usually send my reports through a newsletter first. Join the mailing list at http://www.3footcrowbar.com/ Twitter: https://twitter.com/MattBerry01 Interests: -- reading up on bounded rationality, behaviorism, and philosophy  -- writing down observations and... <a href='/author/matt-berry' sasource='about_more'>More</a>
    </div>
    <div class="cleaner"></div>
	</div>
  <div class="followup_contributor_info_bottom_cnt">
    
    <div class="left_cnt">
      <ul class="followup_contributor_info_content_categories"><li>Blog: <a rel='nofollow' target='_blank' href='http://www.3footcrowbar.com/'>3 Foot Crowbar</a></li> <li>Book: <a rel='nofollow' target='_blank' href='http://www.amazon.com/Mechanics-Virtue-cynics-righteous-behavior/dp/1449598080/ref=sr_1_1?ie=UTF8&s=books&qid=1293332326&sr=8-1'>The Mechanics of Virtue: A cynic's guide to righteous behavior</a></li></ul>
    </div>
  </div>

  <div class="cleaner"></div>
</div>
<div class="followup_contributor_info_on_author_bottom"></div>

          </div>
        </div>
    </div>
    <a href="/author/matt-berry" itemprop="author" class="author_info_name" sasource="about_lname">Matt Berry</a>
    <div class="cleaner"></div>
    <div class="author_info_nav_border">
      <div class="author_info_nav">
        <ul class="the_author_info_nav">
          <li><a href='/author/matt-berry/articles'>Articles <span>(19)</span></a></li>
            <li>
                   <a href='/author/matt-berry/instablog'>Instablog
                     <span>(54)</span>
                   </a>
                 </li>            <li>
                   <a href='/author/matt-berry/stocktalk'>StockTalks <span>(17)</span></a>
                 </li>            <li>
                   <a href='/author/matt-berry/comments'>Comments <span>(210)</span></a>
                 </li>              <script>if (/stats viewer/.test(readCookie("user_perm"))) document.write("<li><a href='/account/authorboard/earnings?for_user_id=582827'>Earnings</a></li>");</script>
          <li><a href='/author/matt-berry'>Profile</a></li>        </ul>
      </div>
    </div>
    <div class="cleaner"></div>
    <div class="user_followers_following">
      <div class="user_followers">
        <a href="/author/matt-berry/followers">
          <span id="followers" class="number followers_number_582827 followers_number_matt-berry">150</span>
          <span class="text">Followers</span>
        </a>
      </div>
      <div class="user_followers">
        <a href="/author/matt-berry/following">
          <span id="followings" class="number">68</span>
          <span class="text">Following</span>
        </a>
      </div>
    </div>

    <div id="follow_this_user" class="follow_this_user"></div>
    <script>Follow.author_sidebar__follow_button_initiator('matt-berry')</script>
    <span class='author_info_send_message' onclick='Messaging.sendMessage("7fqwkxb1", "Article Author ID Card Upper")'>Send Message</span>
    <div class="cleaner"></div>
  </div>
  <div class="follow_popup_wrapper">
      <div class="green_pop_wrapper" id="stop_follow" style="display:none"><div class="green_pop_top_arrow"></div><div class="green_pop"><span class="close_pop" onclick="$('stop_follow').style.display='none'"></span><p><span id="stop_follow_message"></span> Matt Berry</p><span class="stop_following" onclick="Follow.ajax_stop_follow_this_author(this, 'matt-berry')">Stop Following</span></div></div><div class="green_pop_wrapper" id="no_longer_follow" style="display:none"><div class="green_pop_top_arrow"></div><div class="green_pop"><span class="close_pop" onclick="$('no_longer_follow').style.display='none'"></span><p><span id="no_longer_message"></span> Matt Berry</p></div></div>  </div>
</div>
  <script>SeekingAlpha.Initializer.onDOMLoad(function (){Follow.setFfToElements($('followers'),$('followings'),17226)})</script>

    </div>
    <div class="cleaner"></div>
    <span>About this author:</span>
     <ul>
       <li><a target="_blank" href="http://www.marketocracy.com/cgi-bin/WebObjects/Portfolio.woa/ps/FundPublicPage/source=IbLkDcLiEmMfMpKhMaKiAbDd">Visit Rank at Marketocracy</a></li>
    </ul>
<span>By this author:</span>
  <a target='_blank' href="http://www.amazon.com/Mechanics-Virtue-cynics-righteous-behavior/dp/1449598080/ref=sr_1_1?ie=UTF8&s=books&qid=1293332326&sr=8-1"><img class="book_by_author_image large" src="http://static.seekingalpha.com/uploads/2011/1/2/saupload_cm_capture_8.jpg" /></a>
    </div>
          <div class="stickyad_wrapper">
            <div class="item banner160x600" id="fixed_banner160x600">
            </div>
          </div>
      </div>
    </div>
      <script>var page_ad_src = 'http://ad.doubleclick.net/adj/sek.investing-ideas/short-ideas;sz=300x251;x=x;tile=4;d=investing-ideas;pos=b;t=short-ideas;aid=1835142;d=investing-ideas;t=short-ideas;t=us;t=article;z=1;a=matt-berry;cnt=7;cnt=23;cnt=24;pr=aegr;s=aegr;'+dart_my_vocation_and_profiles()+'ord='+ord+'?';</script>
  <div id="ads_and_tools" class="article_sidebar_tools red_sidebar">
    <div class="item banner300x600">
      <script>add_js_to_ad_call('http://ad.doubleclick.net/adj/sek.investing-ideas/short-ideas;sz=300x250,300x600;x=x;tile=2;d=investing-ideas;pos=t;t=short-ideas;aid=1835142;d=investing-ideas;t=short-ideas;t=us;t=article;z=1;a=matt-berry;cnt=7;cnt=23;cnt=24;pr=aegr;s=aegr;'+dart_my_vocation_and_profiles()+'ord='+ord+'?');</script>
    </div>
      <div id="alternative_title_container" class="mini_category data_currencies_table" style="display:none">
  <div class="sidebar_title_bk">
    <span class="sidebar_title_text" id="article_alternative_title"></span>			
  </div>
  <div id="symbol_alternative_tags" class="symbol_alternative_tags"></div>
  <div id="alternatives_pirsomet" class="alternatives_pirsomet" style="float:left;width:100%;"></div>
    <script type="text/javascript">
      ssga_always_display("Article_120x30", "http://9nl.it/i3eb/");
    </script>
  <div class="cleaner"></div>
</div>

<script type="text/javascript">
  symbol = "AEGR";
  new Ajax.Request('/articles/get_ajax_alternatives_by_symbol?symbol='+symbol, {
    asynchronous:true,
    evalScripts:true,
    method:'get',
    onComplete: function(transport) {
      if (transport.status == 200 && transport.responseText != 'failed') {
        response = transport.responseText.split("@@");
        symbolZiignight = new Ziignight('', 'SAlternative',"","symbolZiignight","symbol_alternative_tags","ETF");
        symbolZiignight.WorkJSON = eval(response[1]);
        symbolZiignight.addETF = false;
        symbolZiignight.pageType = 'Article';
        symbolZiignight.selectedSymbol = symbol;
        symbolZiignight.SAlternativePrint(-1,true);
        symbolZiignight.InsertEtfAlternativeSymbol(response[0]);
        $('article_alternative_title').innerHTML = response[0].toUpperCase() + " vs. ETF alternatives";
        $("alternative_title_container").style.display = "";
      }
    }
  });
</script>


    <div id="register_login_snippet"></div>
    
    <div id="side_customize" class="side_customize"></div>
    <div id="portfolio_form_box"></div>

      <div id="article_sidebar" class="article_sidebar">
        <div id="sidebar_down"><img src="http://static.cdn-seekingalpha.com/images/loader_recommended_articles.gif" width="64" height="64" class="loader"/></div>
      </div>

    <div id="articles_on_my_portfolio"></div>
      <div class="cleaner"></div>
      <div class="stickyad_wrapper">
        <div class="item banner300x250" id="article_dart_sticky"></div>
      </div>
       
  </div>

  <script>
      SA.Utils.Ads.add({el:$('article_dart_sticky'), HadCreated:false, size:'300x250', delta:50, info:'http://ad.doubleclick.net/adj/sek.investing-ideas/short-ideas;sz=300x251;x=x;tile=4;d=investing-ideas;pos=b;t=short-ideas;aid=1835142;d=investing-ideas;t=short-ideas;t=us;t=article;z=1;a=matt-berry;cnt=7;cnt=23;cnt=24;pr=aegr;s=aegr;'+dart_my_vocation_and_profiles()+'ord='+ord+'?'});
  </script>

<script src="http://static3.cdn-seekingalpha.com/javascripts/portfolio_form_popup_box_packaged.js?1384857714" type="text/javascript"></script>  
   </div>
  <input id="short_url" type="hidden" value="http://seekingalpha.com/a/13c06" />
</div>

<div id='footer_break'><div></div></div><div id="footer">
  <div id="footernav">
    <div class="footernav_left">
      <a href="http://seekingalpha.com" class="footernav_logo"></a>
      <div class="footernav_boards">
        <div><span class="footer_title">TOP AUTHORS:</span>&nbsp;<a class="top_authors" href="http://seekingalpha.com/leader-board/opinion-leaders">The Opinion Leaders</a></div>
        <div class='top_boards'>
          <span class="footer_title">TOP USERS:</span>
          <a href="http://seekingalpha.com/leader-board/top-stocktalkers">StockTalkers</a> <span class="fl_dash">|</span>
          <a href="http://seekingalpha.com/leader-board/top-instablogs">Instablogs</a>
        </div>    
      </div>
      <div class="cleaner"></div>
    </div>
    
     <div class="footernav_share_buttons">
       <div class="fl">
         <div class="fb-like" data-href="http://www.facebook.com/pages/Seeking-Alpha/224867310939090" data-layout="button_count" data-show-faces="false" data-font="verdana" data-width="450">Follow us</div>
       </div>
      <div class="twitter_wrap ml0 fl"><a href="https://twitter.com/SAlphaTrending" class="twitter-follow-button twitter_share" data-show-count="false">Follow us</a></div>
    </div>
    <div class="footernav_right">
      <div class="footernav_links">
        <a href="http://seekingalpha.com/page/sa-mobile-apps" sasource="footer">Mobile Apps</a>&nbsp;&nbsp;|&nbsp;
        <a class="small_rss" href="http://seekingalpha.com/page/feeds" sasource="footer">&nbsp;&nbsp;&nbsp;&nbsp;RSS Feeds</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/about_us" sasource="footer">About Us</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/contact" sasource="footer">Contact Us</a>
      </div>
      <div class="footernav_more_links">
        <a href="http://seekingalpha.com/page/terms-of-use" sasource="footer">Terms of Use</a> |
        <a href="http://seekingalpha.com/page/privacy" sasource="footer">Privacy</a> |
        <a href="http://www.xignite.com" rel="nofollow" target="_blank">Xignite quote data</a> |
        <span>&#169; 2013 Seeking Alpha</span>
      </div>
      <div class="cleaner"></div>
      
    </div>
   
  </div>
  <div class="cleaner"></div>
</div>  <script type="text/javascript">
    Event.observe(window, 'scroll', check_positions);

    NEW_AD_DELTA = typeof(CHANGE_AD_DELTA) != "undefined" ? CHANGE_AD_DELTA : 0;
    SA.Utils.Ads.add({el:$('fixed_banner160x600'), HadCreated:false, size:'160x600', delta:NEW_AD_DELTA, info:'http://ad.doubleclick.net/adj/sek.investing-ideas/short-ideas;sz=160x600;x=x;tile=3;d=investing-ideas;t=short-ideas;aid=1835142;d=investing-ideas;t=short-ideas;t=us;t=article;z=1;a=matt-berry;cnt=7;cnt=23;cnt=24;pr=aegr;s=aegr;'+dart_my_vocation_and_profiles()+'ord='+ord+'?'});
  </script>
<script>
  document.observe('dom:loaded', function(){
    if ($('article_source')) {$('article_source').hide();}
    if (!is_pro) {$$('.arich_promobox').each(function(o){o.show()})}
    SA.Pages.Article.primary = "aegr";
    SA.Pages.Article.init();
    if (typeof(propromotion) != "undefined") {propromotion();}

    if (SA.Pages.Article.alpha_rich_article() || SA.Pages.Article.insiders_report_article()){
      update_pro_tracker(0,1,0,0);
    }
      
    if (location.href.match(/source=[a-z0-9_]*email[a-z0-9_]*/)) {createCookie('camefromrta',true);}
    var pagination_version = ABTest.identity%10;

    if (SA.Pages.Article.is_roadblock()){
      rb = new roadblock('article');
      rb.register_show = SA.Pages.Article.roadshow;
      Mone.event(rb.type,rb.source,"Half Article");
      SA.Pages.Article.cut_new(pagination_version);
    } else {
      if (!SA.Data.User.loggedIn() && (location.search.match(/[?&]source=(yahoo|nasdaq)/)) && !document.cookie.match(/\b(user_id|user_email|camefromrta)=/)) {
        SA.Pages.Article.hide_features_for_roadblock();
      }
    }
    if (/no_ads/i.test(window.location.href)) {SA.Pages.Article.strip_for_iframe()}

      SA.Pages.Article.btb();

  });
    SeekingAlpha.Initializer.AddAfterLoad(function(){ 
      SA.Pages.Article.articlePromo({"allSlugs":["aegr"],"primarySlug":"aegr","dashboard_id":10727,"dashboard_title":"Investing Ideas"});
    });
</script>
      <script src="http://static.cdn-seekingalpha.com/javascripts/jspell_packaged.js?1384857715" type="text/javascript"></script>
<link href="http://static2.cdn-seekingalpha.com/stylesheets/footer_packaged.css?1384857741" media="screen" rel="stylesheet" type="text/css" /><script type="text/javascript">
  if(typeof (authors) == "undefined" || typeof (symbols) == "undefined")
    load_remote_script("http://static3.cdn-seekingalpha.com/javascripts/sa.js?1384857688");
  if(is_users_cookie_exists() && !cookieExists('tops') && typeof(tops) == "undefined")
    load_remote_script("http://static1.cdn-seekingalpha.com/javascripts/tops.js?1384857412");
  Mone.renderedParams = {};
  SeekingAlpha.Initializer.AddAfterLoad(function(){SA.Performance.Utils.loadPrintStyle('http://static1.cdn-seekingalpha.com/stylesheets/print.css')});
</script>
<noscript>
  <img src="http://b.scorecardresearch.com/p?c1=2&c2=8500672&cv=2.0&cj=1" width="0" height="0" />
</noscript>
<script src="http://static2.cdn-seekingalpha.com/javascripts/footer_packaged.js?1384857713" type="text/javascript"></script><div id="symbol_data_script_container"></div>
<script type="text/javascript">
SeekingAlpha.Initializer.onDOMLoad(function(){
  if(SA.Pages && SA.Pages.Account && SA.Pages.Account.Portfolios){
    var a = SA.Pages.Account.Portfolios.alertsTab;
    SA.Pages.Account.Portfolios.alertsTab = function(b){if ($('ziignight_submit')) a(b);}
if (getURLParam("pu")=="all_holdings") $("tab_"+Portfolio.current_tab).click();  
}
});
if (/\/account\/portfolio/.test(location.href)) {document.getElementsByTagName("html")[0].style.overflow = "auto"}
</script>
<style>
.portfolio_news #content_wrapper .left_content .market_currents ul#mc_news li  .bullet{* position: static;* padding:0 6px 6px 1px;}
</style>
<script>
var pubnub_test = '$|892165|17136652|12809951|52832|234601|946066|138138|119840|158117|3|6383|531163|9393711|4726401|1107427|2120371|2632411|';
try{
var auth = "|" + SA.Data.Cookies.get('user_id') + "|";
if (pubnub_test.indexOf(auth) > 0) {
var scriptElement_n = document.createElement("script");
scriptElement_n.defer = "defer";
scriptElement_n.src = 'http://static.cdn-seekingalpha.com/javascripts/utils/notify.js?144';
document.getElementsByTagName("head")[0].appendChild(scriptElement_n);
var scriptElement = document.createElement("script");
scriptElement.defer = "defer";
scriptElement.src = 'http://static.cdn-seekingalpha.com/javascripts/chat.js?148';
document.getElementsByTagName("head")[0].appendChild(scriptElement);
var fileref=document.createElement("link")
fileref.setAttribute("rel", "stylesheet")
fileref.setAttribute("type", "text/css")
fileref.setAttribute("href", "http://static.cdn-seekingalpha.com/stylesheets/chat.css?147")
document.getElementsByTagName("head")[0].appendChild(fileref)
}
} catch(e) {
}
</script>

<script type="text/javascript">if (typeof NREUMQ !== "undefined") { if (!NREUMQ.f) { NREUMQ.f=function() {
NREUMQ.push(["load",new Date().getTime()]);
var e=document.createElement("script");
e.type="text/javascript";
e.src=(("http:"===document.location.protocol)?"http:":"https:") + "//" +
  "js-agent.newrelic.com/nr-100.js";
document.body.appendChild(e);
if(NREUMQ.a)NREUMQ.a();
};
NREUMQ.a=window.onload;window.onload=NREUMQ.f;
};
NREUMQ.push(["nrfj","beacon-5.newrelic.com","c0370b1d43","334927,334964","cldeEUAJWgldEBsASkVRUwlXFRkWUA1D",0,50,new Date().getTime(),"","","","",""]);}</script>
    <div class="cleaner"></div>
  </body>
</html>
